Eisai and Biogen Japan will continue to contribute to the advancement of Alzheimer’s disease treatment through ongoing collaboration with academia.

Phase 1/2 data showed a median overall survival (“mOS”) of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone notes Intensity Therapeutics.

SenoVax has previously been demonstrated to reduce lung cancer growth1, which was the subject of the Company’s IND #307452. It has also been shown to accelerate recovery of blood cell production after chemotherapy notes Immorta Bio.

BioHub Maryland is a skills-first workforce development initiative of the Maryland Tech Council (MTC), the state’s largest life sciences and technology trade association. Its mission is to accelerate the growth of the life sciences industry by expanding the state’s biopharma manufacturing talent pipeline.

“This partnership with Cryoport reflects our dedication to providing patients and clinics with the highest standard of care,” said Louis Villalba, TMRW’s CEO. “Cryoport’s reputation for excellence in reproductive biologistics, paired with TMRW’s cutting-edge specimen management technology and safety certifications, delivers unmatched security and peace of mind for transporting specimens in the fertility space.”

Revolo Biotherapeutics notes additionally, the data continues to demonstrate the differentiated upstream MOA of ‘1104, restoring immune homeostasis by impacting both the effector and regulatory arms of the immune system with a persistence of effect for multiple weeks.